<!DOCTYPE html>
<html lang="en">
<head>
  
  
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    
    
    <link rel="canonical" href="https://jzpero.github.io/mednotes/Respirology/Airway%20Disease/Allergic%20Asthma/">
    <link rel="shortcut icon" href="../../../img/favicon.ico">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />
    <title>Allergic Asthma - MedNotes</title>
    <link href="../../../css/bootstrap-3.3.7.min.css" rel="stylesheet">
    <link href="../../../css/font-awesome-4.7.0.css" rel="stylesheet">
    <link href="../../../css/base.css" rel="stylesheet">
    <link rel="stylesheet" href="../../../css/highlight.css">
    <!-- HTML5 shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!--[if lt IE 9]>
        <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
        <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <script src="../../../js/jquery-3.2.1.min.js"></script>
    <script src="../../../js/bootstrap-3.3.7.min.js"></script>
    <script src="../../../js/highlight.pack.js"></script>
    
    <base target="_top">
    <script>
      var base_url = '../../..';
      var is_top_frame = false;
        
        var pageToc = [
          {title: "Diagnosis of Asthma", url: "#_top", children: [
              {title: "Contraindications to Bronchial Challenge Testing", url: "#contraindications-to-bronchial-challenge-testing" },
              {title: "Asthma Mimics", url: "#asthma-mimics" },
          ]},
          {title: "Assessing Control", url: "#assessing-control", children: [
              {title: "Uncontrolled vs Severe Asthma", url: "#uncontrolled-vs-severe-asthma" },
          ]},
          {title: "Asthma Treatment (GINA 2023)", url: "#asthma-treatment-gina-2023", children: [
              {title: "Reliever Medication", url: "#reliever-medication" },
              {title: "Controller Medications", url: "#controller-medications" },
              {title: "Non-Pharmacological", url: "#non-pharmacological" },
              {title: "LTRA", url: "#ltra" },
              {title: "Management of Severe Asthma", url: "#management-of-severe-asthma" },
              {title: "Biologic Asthma Therapy", url: "#biologic-asthma-therapy" },
              {title: "Special Populations", url: "#special-populations" },
          ]},
          {title: "References", url: "#references", children: [
          ]},
        ];

    </script>
    <script src="../../../js/base.js"></script> 
</head>

<body>
<script>
if (is_top_frame) { $('body').addClass('wm-top-page'); }
</script>



<div class="container-fluid wm-page-content">
  <a name="_top"></a>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Asthma%20Attacks/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Asthma%20Attacks/" class="btn btn-xs btn-link">
        Acute Asthma Management
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../../Upper%20Lobe-Predominant%20Diseases%20of%20the%20Lung/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../../Upper%20Lobe-Predominant%20Diseases%20of%20the%20Lung/" class="btn btn-xs btn-link">
        Upper Lobe Predominant Diseases of the Lung
      </a>
    </div>
    
  </div>

    

    <p>Asthma is a heterogenous disease characterized by chronic airway inflammation. Symptoms include wheeze, shortness of breath, chest tightness and cough that vary over time and are related to bronchoconstriction, airway wall thickening, increased mucus and variable expiratory airflow limitation.</p>
<div class="admonition note">
<p class="admonition-title">Relevant Guidelines</p>
<p>GINA 2021 Guidelines</p>
</div>
<h1 id="diagnosis-of-asthma">Diagnosis of Asthma</h1>
<ul>
<li>
<p>Diagnosis requires a:</p>
<ul>
<li><strong>History of variable symptoms</strong> (wheeze, SOB, chest tightness, cough) which are variable over time and variable in intensity; often worse at night or on waking; often triggered by exercise, laughter, allergens, and cold air; worsened with viral infections.</li>
<li><strong>Confirmed variable expiratory airflow limitation</strong><ul>
<li>(1) <strong>Positive spirometry with reversible airway obstruction:</strong> FEV1/FVC &lt; LLN; and increase in FEV1 after bronchodilator or after a course of controller therapy of &gt;=12% and a minimum of 200 mL</li>
<li>(2) <strong>Peak expiratory flow</strong><ul>
<li>&gt;60LPM (min 20%) increase after bronchodilator or after a course of controller therapy</li>
<li>Diurnal variation &gt; 8% based on twice-daily readings, or &gt;20% based on multiple daily readins</li>
</ul>
</li>
<li>(3) <strong>Positive challenge test</strong> <ul>
<li>Methacholine PC20 &lt;4 mg/mL or PD20 &lt;0.5 umol</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Expiratory airflow limitation</strong>, at least once during the diagnostic process, confirmed with reduced FEV1/FVC below the LLN</p>
</li>
<li><strong>Variability,</strong> demonstrated by one of:<ol>
<li>Positive bronchodilator reversibility (10-15 minutes post 200-400 mcg salbutamol) -- improvement in FEV1 by &gt;12% and 200 mL post BD</li>
<li>Improvement with anti-inflammatory treatment x 4 weeks -- improvement in FEV1 by &gt;12% and 200 mL</li>
<li>Excessive FEV1 variation in lung function between visits (improvement in FEV1 by &gt;12% and 200 mL)</li>
<li>Peak flow variability &gt; 10%</li>
<li>Positive bronchial challenge test<ol>
<li>Methacholine challenge. Look for a drop in FEV1 by 20%:<ol>
<li>PC20 &lt; 4 mg/mL = positive</li>
<li>PC20 4 - 16 = borderline</li>
<li>PC20 &gt; 16 negative</li>
</ol>
</li>
<li>Exercise challenge: fall in FEV of &gt;10% and 200 mL</li>
</ol>
</li>
</ol>
</li>
</ul>
<h2 id="contraindications-to-bronchial-challenge-testing">Contraindications to Bronchial Challenge Testing</h2>
<p><img alt="" src="../_attachments/Pasted%20image%2020231010182512.png" /></p>
<h2 id="asthma-mimics">Asthma Mimics</h2>
<ul>
<li>Bronchiectasis</li>
<li>Cystic Fibrosis</li>
<li><a href="../../../Rheumatology/ANCA%20Associated%20Vasculitis/">EGPA</a></li>
<li>Vocal cord dysfunction</li>
<li><a href="../../Allergic%20Bronchopulmonary%20Aspergillosus%20%28ABPA%29/">ABPA</a></li>
<li>Reactive airways dysfunction syndrome (RADS) -- acute irritant induced asthma following a single high dose exposure to irritant. Lasts &gt;3 months. Treat like an asthma exacerbation</li>
</ul>
<h1 id="assessing-control">Assessing Control</h1>
<p>Control is the goal of asthma management (i.e. symptoms and risk of adverse outcomes). Assess at each visit. Asthma control implies all of the following CTS criteria:</p>
<p><img alt="" src="../_attachments/Pasted%20image%2020231010183149.png" /></p>
<h2 id="uncontrolled-vs-severe-asthma">Uncontrolled vs Severe Asthma</h2>
<ul>
<li>uncontrolled: poor symptom control, frequent exacerbations, severe hospitalization in the past year, sustained airflow reduction. Usually due to poor adherence, technique, or ongoing trigger.</li>
<li>Severe (5% of patients): requiring treatment with high-dose ICS + 2nd controller for the previous year, or oral steroids for 50% of the year, to prevent it from becoming uncontrolled. Please refer for specialty consultation and add-on therapies.</li>
</ul>
<h1 id="asthma-treatment-gina-2023">Asthma Treatment (GINA 2023)</h1>
<h2 id="reliever-medication">Reliever Medication</h2>
<ol>
<li>Low-dose ICS + SABA (e.g. budesonide-formoterol -- Symbicort) is the preferred reliever medication for all asthmatics.<ul>
<li>based on the principle that asthma is an inflammatory condition</li>
<li>SABA PRN alone increases the risk of exacerbation, decreased lung function, severe exacerbations.</li>
<li><strong>SYGMA 1 + 2 trials (NEJM 2018)</strong> showed that PRN Symbicort is superior to SABA PRN in reducing exacerbations (64%) and non-inferior to maintenance ICS + PRN SABA.</li>
</ul>
</li>
<li>Alternative reliever: PRN SABA</li>
</ol>
<h2 id="controller-medications">Controller Medications</h2>
<table>
<thead>
<tr>
<th>Control level</th>
<th>Preferred controller</th>
<th>Alternatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms less than twice monthly</td>
<td>PRN low-dose ICS-formoterol</td>
<td>Low-dose ICS whenever a SABA is taken</td>
</tr>
<tr>
<td>Symptoms less than daily</td>
<td>Daily low-dose ICS, or PRN low-dose ICS-formoterol</td>
<td>Daily leukotriene receptor antagonist [LTRA] or low-dose ICS whenever a SABA is taken</td>
</tr>
<tr>
<td>Symptoms most days or waking with asthma more than once weekly</td>
<td>Low-dose ICS-LABA</td>
<td>Medium-dose ICS, or low dose ICS + LTRA</td>
</tr>
<tr>
<td>Symptoms most days or waking with asthma more than once weekly, and low lung function</td>
<td>Medium-dose ICS-LABA</td>
<td>High-dose ICS, add-on tiotropium, or add-on LTRA</td>
</tr>
<tr>
<td>"Severe Asthma"</td>
<td>High-dose ICS-LABA. Refer for phenotypic assessment +/- add on tiotropium, anti-IgE, anti-IL5, anti-IL4</td>
<td>Add low-dose OCS</td>
</tr>
</tbody>
</table>
<ul>
<li>Never use LABA monotherapy - increased risk of death.</li>
</ul>
<p><img alt="" src="../_attachments/Pasted%20image%2020221025231713.png" /></p>
<h2 id="non-pharmacological">Non-Pharmacological</h2>
<ul>
<li>confirm diagnosis, asthma action plan</li>
<li>weight loss, exercise training</li>
<li>allergen and trigger avoidance, allergen immunotherapy</li>
<li>smoking cessation</li>
<li>vaccinations</li>
<li>avoid NSAIDs/beta blockers if possible</li>
</ul>
<h2 id="ltra">LTRA</h2>
<ul>
<li>may be appropriate as initial controlled if ICS not possible for some reasons, but less effective than ICS at prevention exacerbations.<ul>
<li>most effective in aspirin-exacerbated asthma, exercise-induced symptoms, allergic rhinitis</li>
<li>FDA black box warning: increased suicidality in adolescents and adults</li>
</ul>
</li>
<li>LABA-ICS is superior to ICS-LTRA for those stepping up from low-dose ICS maintenance</li>
</ul>
<h2 id="management-of-severe-asthma">Management of Severe Asthma</h2>
<ul>
<li><strong>Workup</strong><ul>
<li>Total IgE</li>
<li>peripheral eosinophil count</li>
<li>sputum eosinophilis and FeNO where available</li>
</ul>
</li>
<li><strong>Treatment (see above GINA table)</strong><ul>
<li>tiotropium mist inhaler --&gt; increases time to first severe exacerbation</li>
<li>Macrolides if uncontrolled despite ICS/LABA. <strong>LANCET AMAZES trial 2017</strong></li>
<li>Biologics</li>
<li>Low-dose OCS</li>
<li>Bronchial thermoplasty</li>
</ul>
</li>
</ul>
<h2 id="biologic-asthma-therapy">Biologic Asthma Therapy</h2>
<p>Used for uncontrolled severe asthma.</p>
<table>
<thead>
<tr>
<th>MOA</th>
<th>Agents</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-IgE</td>
<td>Omalizumab</td>
<td>Allergic asthma IgE 30-700, sensitive to a perennial allergen, or severe despite high dose ICS and one other controller.</td>
</tr>
<tr>
<td>Anti-IL5</td>
<td>Mepolizumab, resilzumab, benralizumab</td>
<td>Severe eosinophilic asthma (&gt;300), and recurrent exacerbations despite high-dose ICS and one other controller</td>
</tr>
<tr>
<td>Anti-IL4</td>
<td>Dupilumab</td>
<td>Not yet in guidelines. Two trials in NEJM 2018.</td>
</tr>
</tbody>
</table>
<h2 id="special-populations">Special Populations</h2>
<table>
<thead>
<tr>
<th>Population</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seasonal allergic asthma</td>
<td>start ICS immediately when symptoms commence, and continue for 4 weeks after the relevant pollen season ends</td>
</tr>
<tr>
<td>Exercise induced</td>
<td>Salbutamol pre-exercise, if needed add LTRA pre-exercise, if needed try regular ICS</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Continue ICS/oral steroids if exacerbating, most evidence for budesonide</td>
</tr>
<tr>
<td>ASA exacerbated respiratory disease</td>
<td>Avoid ASA/NSAIDs, treat like normal, good response to LTRA. Desensitive to ASA if needed.</td>
</tr>
</tbody>
</table>
<h1 id="references">References</h1>
<ol>
<li>IMR slides 2021</li>
<li>GINA 2020</li>
<li>CTS 2017</li>
</ol>

  <br>
    

    
    
      
    

  <div class="row wm-article-nav-buttons" role="navigation" aria-label="navigation">
    
    <div class="wm-article-nav pull-right">
      <a href="../Asthma%20Attacks/" class="btn btn-xs btn-default pull-right">
        Next
        <i class="fa fa-chevron-right" aria-hidden="true"></i>
      </a>
      <a href="../Asthma%20Attacks/" class="btn btn-xs btn-link">
        Acute Asthma Management
      </a>
    </div>
    
    <div class="wm-article-nav">
      <a href="../../Upper%20Lobe-Predominant%20Diseases%20of%20the%20Lung/" class="btn btn-xs btn-default pull-left">
        <i class="fa fa-chevron-left" aria-hidden="true"></i>
        Previous</a><a href="../../Upper%20Lobe-Predominant%20Diseases%20of%20the%20Lung/" class="btn btn-xs btn-link">
        Upper Lobe Predominant Diseases of the Lung
      </a>
    </div>
    
  </div>

    <br>
</div>

<footer class="container-fluid wm-page-content">
  <p>Documentation built with <a href="https://www.mkdocs.org/">MkDocs</a> using <a href="https://github.com/gristlabs/mkdocs-windmill">Windmill</a> theme by Grist Labs.</p>
</footer>

</body>
</html>